Your browser doesn't support javascript.
loading
Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment.
Dacic, Sanja; Cao, Xuanye; Bota-Rabassedas, Neus; Sanchez-Espiridion, Beatriz; Berezowska, Sabina; Han, Yuchen; Chung, Jin-Haeng; Beasley, Mary Beth; Dongmei, Lin; Hwang, David; Mino-Kenudson, Mari; Minami, Yuko; Papotti, Mauro; Rekhtman, Natasha; Roden, Anja C; Thunnissen, Erik; Tsao, Ming-Sound; Yatabe, Yasushi; Yoshida, Akihiko; Wang, Linghua; Hartman, Douglas J; Jerome, Jacob A; Kadara, Humam; Chou, Teh-Ying; Wistuba, Ignacio I.
Affiliation
  • Dacic S; Department of Pathology University of Pittsburgh, Pittsburgh, Pennsylvania. Electronic address: sanja.dacic@yale.edu.
  • Cao X; Department of Translational Molecular Pathology, The University of Texas M. D. Anderson, Houston, Texas.
  • Bota-Rabassedas N; Department of Translational Molecular Pathology, The University of Texas M. D. Anderson, Houston, Texas.
  • Sanchez-Espiridion B; Department of Translational Molecular Pathology, The University of Texas M. D. Anderson, Houston, Texas.
  • Berezowska S; Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Han Y; Department of Pathology, Shanghai Chest Hospital, Shanghai, People's Republic of China.
  • Chung JH; Department of Pathology and Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Beasley MB; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Dongmei L; Department of Pathology, Beijing Cancer Center, Beijing, People's Republic of China.
  • Hwang D; Sunnybrook Health Sciences Centre, Odette Cancer Centre, Ontario, Canada.
  • Mino-Kenudson M; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Minami Y; Department of Pathology, National Hospital Organization Ibarakihigashi National Hospital, The Center of Chest Diseases and Severe Motor & Intellectual Disabilities, Tokai, Ibaraki, Japan.
  • Papotti M; Department of Pathology, University of Turin, Torino, Italy.
  • Rekhtman N; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Roden AC; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Thunnissen E; Department of Pathology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Tsao MS; Department of Pathology, University Health Network and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Yatabe Y; Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
  • Yoshida A; Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
  • Wang L; Department of Translational Molecular Pathology, The University of Texas M. D. Anderson, Houston, Texas.
  • Hartman DJ; Department of Pathology University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Jerome JA; Department of Pathology University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Kadara H; Department of Translational Molecular Pathology, The University of Texas M. D. Anderson, Houston, Texas.
  • Chou TY; Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Wistuba II; Department of Translational Molecular Pathology, The University of Texas M. D. Anderson, Houston, Texas.
J Thorac Oncol ; 19(2): 273-284, 2024 02.
Article in En | MEDLINE | ID: mdl-37717856
ABSTRACT

INTRODUCTION:

Morphologic and molecular data for staging of multifocal lung squamous cell carcinomas (LSCCs) are limited. In this study, whole exome sequencing (WES) was used as the gold standard to determine whether multifocal LSCC represented separate primary lung cancers (SPLCs) or intrapulmonary metastases (IPMs). Genomic profiles were compared with the comprehensive morphologic assessment.

METHODS:

WES was performed on 20 tumor pairs of multifocal LSCC and matched normal lymph nodes using the Illumina NovaSeq6000 S4-Xp (Illumina, San Diego, CA). WES clonal and subclonal analysis data were compared with histologic assessment by 16 thoracic pathologists. In addition, the immune gene profiling of the study cases was characterized by the HTG EdgeSeq Precision Immuno-Oncology Panel.

RESULTS:

By WES data, 11 cases were classified as SPLC and seven cases as IPM. Two cases were technically suboptimal. Analysis revealed marked genomic and immunogenic heterogeneity, but immune gene expression profiles highly correlated with mutation profiles. Tumors classified as IPM have a large number of shared mutations (ranging from 33.5% to 80.7%). The agreement between individual morphologic assessments for each case and WES was 58.3%. One case was unanimously interpreted morphologically as IPM and was in agreement with WES. In a further 17 cases, the number of pathologists whose morphologic interpretation was in agreement with WES ranged from two (one case) to 15 pathologists (one case) per case. Pathologists showed a fair interobserver agreement in the morphologic staging of multiple LSCCs, with an overall kappa of 0.232.

CONCLUSIONS:

Staging of multifocal LSCC based on morphologic assessment is unreliable. Comprehensive genomic analyses should be adopted for the staging of multifocal LSCC.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Squamous Cell / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Humans Language: En Journal: J Thorac Oncol Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Squamous Cell / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Humans Language: En Journal: J Thorac Oncol Year: 2024 Document type: Article